Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 313

1.

Successful maintenance on sulphonylurea therapy and low diabetes complication rates in a HNF1A-MODY cohort.

Bacon S, Kyithar MP, Rizvi SR, Donnelly E, McCarthy A, Burke M, Colclough K, Ellard S, Byrne MM.

Diabet Med. 2016 Jul;33(7):976-84. doi: 10.1111/dme.12992. Epub 2015 Nov 17.

PMID:
26479152
2.

A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin.

Shepherd MH, Shields BM, Hudson M, Pearson ER, Hyde C, Ellard S, Hattersley AT, Patel KA; UNITED study.

Diabetologia. 2018 Dec;61(12):2520-2527. doi: 10.1007/s00125-018-4728-6. Epub 2018 Sep 18.

3.
4.

Maturity onset diabetes of the young: Seek and you will find.

Heuvel-Borsboom H, de Valk HW, Losekoot M, Westerink J.

Neth J Med. 2016 Jun;74(5):193-200. Review.

5.

Treatment of young patients with HNF1A mutations (HNF1A-MODY).

Raile K, Schober E, Konrad K, Thon A, Grulich-Henn J, Meissner T, Wölfle J, Scheuing N, Holl RW; DPV Initiative the German BMBF Competence Network Diabetes Mellitus.

Diabet Med. 2015 Apr;32(4):526-30. doi: 10.1111/dme.12662. Epub 2014 Dec 30.

PMID:
25483937
6.

A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus.

Hohendorff J, Szopa M, Skupien J, Kapusta M, Zapala B, Platek T, Mrozinska S, Parpan T, Glodzik W, Ludwig-Galezowska A, Kiec-Wilk B, Klupa T, Malecki MT.

Endocrine. 2017 Aug;57(2):272-279. doi: 10.1007/s12020-017-1341-2. Epub 2017 Jun 7.

7.

Maturity onset diabetes of the young: identification and diagnosis.

McDonald TJ, Ellard S.

Ann Clin Biochem. 2013 Sep;50(Pt 5):403-15. doi: 10.1177/0004563213483458. Epub 2013 Jul 22. Review.

PMID:
23878349
8.

MODY in Ukraine: genes, clinical phenotypes and treatment.

Globa E, Zelinska N, Elblova L, Dusatkova P, Cinek O, Lebl J, Colclough K, Ellard S, Pruhova S.

J Pediatr Endocrinol Metab. 2017 Oct 26;30(10):1095-1103. doi: 10.1515/jpem-2017-0075.

PMID:
28862987
9.

Circulating CD36 is reduced in HNF1A-MODY carriers.

Bacon S, Kyithar MP, Schmid J, Costa Pozza A, Handberg A, Byrne MM.

PLoS One. 2013 Sep 12;8(9):e74577. doi: 10.1371/journal.pone.0074577. eCollection 2013.

10.

A case of new mutation in maturity-onset diabetes of the young type 3 (MODY 3) responsive to a low dose of sulphonylurea.

Jesić MD, Sajić S, Jesić MM, Maringa M, Micić D, Necić S.

Diabetes Res Clin Pract. 2008 Jul;81(1):e1-3. doi: 10.1016/j.diabres.2008.03.005. Epub 2008 Apr 22.

PMID:
18433912
11.

Systematic assessment of etiology in adults with a clinical diagnosis of young-onset type 2 diabetes is a successful strategy for identifying maturity-onset diabetes of the young.

Thanabalasingham G, Pal A, Selwood MP, Dudley C, Fisher K, Bingley PJ, Ellard S, Farmer AJ, McCarthy MI, Owen KR.

Diabetes Care. 2012 Jun;35(6):1206-12. doi: 10.2337/dc11-1243. Epub 2012 Mar 19.

13.

Half-Life of Sulfonylureas in HNF1A and HNF4A Human MODY Patients is not Prolonged as Suggested by the Mouse Hnf1a(-/-) Model.

Urbanova J, Andel M, Potockova J, Klima J, Macek J, Ptacek P, Mat'oska V, Kumstyrova T, Heneberg P.

Curr Pharm Des. 2015;21(39):5736-48. Review.

PMID:
26446475
14.

Identification of HNF1A-MODY and HNF4A-MODY in Irish families: phenotypic characteristics and therapeutic implications.

Kyithar MP, Bacon S, Pannu KK, Rizvi SR, Colclough K, Ellard S, Byrne MM.

Diabetes Metab. 2011 Dec;37(6):512-9. doi: 10.1016/j.diabet.2011.04.002. Epub 2011 Jun 16.

PMID:
21683639
15.

A genetic diagnosis of HNF1A diabetes alters treatment and improves glycaemic control in the majority of insulin-treated patients.

Shepherd M, Shields B, Ellard S, Rubio-Cabezas O, Hattersley AT.

Diabet Med. 2009 Apr;26(4):437-41. doi: 10.1111/j.1464-5491.2009.02690.x.

PMID:
19388975
16.

Maturity onset diabetes of the young due to HNF1A variants in Croatia.

Pavić T, Juszczak A, Pape Medvidović E, Burrows C, Šekerija M, Bennett AJ, Ćuća Knežević J, Gloyn AL, Lauc G, McCarthy MI, Gornik O, Owen KR.

Biochem Med (Zagreb). 2018 Jun 15;28(2):020703. doi: 10.11613/BM.2018.020703. Epub 2018 Apr 15.

17.

[A 20-year prospective follow-up study to evaluate the development of retinopathy and nephropathy after the onset of type 1 diabetes mellitus: Contribution of glycemic control and metabolic memory].

Bolotskaya LL, Bessmertnaya EG, Shestakova MV, Shamkhalova MS, Nikankina LV, Ilyin AV, Glek IS, Zolotukhin AV, Dedov II.

Ter Arkh. 2017;89(10):17-21. doi: 10.17116/terarkh2017891017-21. Russian.

PMID:
29171465
18.

Diabetic ketoacidosis in the setting of HNF1A-maturity onset diabetes of the young.

Egan AM, Cunningham A, Jafar-Mohammadi B, Dunne FP.

BMJ Case Rep. 2015 Apr 2;2015. pii: bcr2014209163. doi: 10.1136/bcr-2014-209163.

19.

Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort.

de Boer IH, Rue TC, Cleary PA, Lachin JM, Molitch ME, Steffes MW, Sun W, Zinman B, Brunzell JD; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group, White NH, Danis RP, Davis MD, Hainsworth D, Hubbard LD, Nathan DM.

Arch Intern Med. 2011 Mar 14;171(5):412-20. doi: 10.1001/archinternmed.2011.16.

20.

Cardiovascular risk factors and complications associated with albuminuria and impaired renal function in insulin-treated diabetes.

Doggen K, Nobels F, Scheen AJ, Van Crombrugge P, Van Casteren V, Mathieu C.

J Diabetes Complications. 2013 Jul-Aug;27(4):370-5. doi: 10.1016/j.jdiacomp.2013.02.008. Epub 2013 Mar 26.

PMID:
23537603

Supplemental Content

Support Center